Sign in
Taking people in United StatesNo phase

App-Based Study of Daily Life and Treatment in IgA Nephropathy

Follows adults with IgA nephropathy, a kidney disease, through symptoms, treatments and quality of life.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Boston, United StatesSee the site
Trial code
Registry title
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Status
Recruiting
People taking part
300 people, planned
Started
4 Mar 2025
Planned end
30 Jun 2025
Type of study
Observational, 4 groups
Treatments tested
  • Other treatment
  • Iptacopan
  • Atrasentan
Record updated
17 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in the US who have IgA nephropathy, and for adult caregivers of patients with IgAN. Participants use a mobile app and read English.

Age
18 years or older. Caregivers must be adults too; the patient they care for can be an adult or a child under 18.
Sex
All sexes can join.
Disease stage
Diagnosis of IgAN, regardless of symptoms or treatment history.
Earlier treatment
None required. Any treatment history is fine.

Main reasons for not taking part

  • Not based in the US
  • Cannot read and understand English

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Diagnosis of IgAN, regardless of symptom or treatment history
  • Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
  • US-based with a proficient understanding of and ability to read the English language

Who cannot take part

  • None

Where in United States

  • Boston, MassachusettsHospital not named in the registryContact: Novartis PharmaceuticalsTaking people

About the trial

What the trial wants to find out

The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.

The 4 groups in the trial

  • Immunoglobulin A nephropathy (IgAN)-Iptacopan

    IgAN patients taking iptacopan and their caregivers

    Treatment: Iptacopan

  • IgAN-atrasentan

    IgAN patients taking atrasentan and their caregivers

    Treatment: Atrasentan

  • IgAN-other treatment

    IgAN patients taking other specific treatment and their caregivers

    Treatment: Other treatment

  • IgAN-no treatment

    IgAN patients taking none treatment and their caregivers

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Plain-language title
App-Based Study of Daily Life and Treatment in IgA NephropathyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 June 2025